Ginkgo Bioworks DNA Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$312.76M+42.8% | -$547.03M+38.7% | -$892.87M+57.6% | -$2.11B-16.5% | ||
| $58.99M-6.4% | $63.02M-10.6% | $70.51M+65.7% | $42.55M+46.3% | ||
| $81.55M-27.4% | $112.34M-51.1% | $229.88M-88.1% | $1.93B+20.2% | ||
| -$1.36M-45.7% | -$936K-16.9% | -$801K+94.5% | -$14.61M— | ||
| —— | —— | -$50.07M— | —— | ||
| —— | -$40.44M-339% | $16.9M+142% | -$40.67M-191% | ||
| —— | —— | -$2.57M-179% | -$921K— | ||
| $12.16M— | —— | $452K— | —— | ||
| -$2.17M— | —— | -$3.19M— | —— | ||
| -$32.39M+52.8% | -$68.65M-91.1% | -$35.92M+1.4% | -$36.42M-230% | ||
| $30.08M+7.1% | $28.1M-0.8% | $28.31M— | —— | ||
| -$27.93M-84.8% | -$15.11M+33.7% | -$22.8M— | —— | ||
| -$171.06M+46.5% | -$319.59M-8.2% | -$295.5M-17.2% | -$252.2M+0.6% | ||
| $7.67M-87.7% | $62.54M+53.3% | $40.8M-21.9% | $52.27M-7.5% | ||
| $418.63M— | $0— | $0— | —— | ||
| $25.9M— | —— | $0— | —— | ||
| —— | -$538K-154% | $990K— | —— | ||
| —— | -$62.24M+22.9% | -$80.69M— | —— | ||
| $354K-60.5% | $897K-30.7% | $1.3M+4.7% | $1.24M+10.2% | ||
| $0— | $0-100% | $23K— | —— | ||
| $17.78M+1,122% | -$1.74M+45.9% | -$3.22M-103% | $95.34M-93.8% | ||
| —— | -$281K— | —— | $908K— | ||
| —— | -$383.84M-1.0% | -$380M— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$27.93M-84.8% | -$15.11M+33.7% | -$22.8M— | —— | ||
| —— | -$40.44M-339% | $16.9M+142% | -$40.67M-191% | ||
| $12.16M— | —— | $452K— | —— | ||
| —— | -$10.09M— | —— | $8.52M+136% | ||
| —— | -$23.46M-153% | -$9.28M+29.9% | -$13.23M— | ||
| $0+100% | -$1.12M+18.6% | -$1.37M+96.0% | -$34.26M-41.7% | ||
| $30.08M+7.1% | $28.1M-0.8% | $28.31M— | —— | ||
| -$2.17M— | —— | -$3.19M— | —— | ||
| —— | -$538K-154% | $990K— | —— | ||
| $0— | $0-100% | $350K-99.1% | $40M— | ||
| —— | —— | $0— | —— | ||
| $354K-60.5% | $897K-30.7% | $1.3M+4.7% | $1.24M+10.2% | ||
| —— | —— | —— | —— | ||
| -$32.39M+52.8% | -$68.65M-91.1% | -$35.92M+1.4% | -$36.42M-230% | ||
| -$27.93M-84.8% | -$15.11M+33.7% | -$22.8M— | —— | ||
| -$178.72M+53.2% | -$382.13M-13.6% | -$336.3M-10.5% | -$304.47M+1.9% | ||
| -$178.72M+53.2% | -$382.13M-13.6% | -$336.3M-10.5% | -$304.47M+1.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ginkgo Bioworks generate?
- Ginkgo Bioworks (DNA) generated -$166.2M in operating cash flow over the trailing twelve months.
- What is Ginkgo Bioworks's free cash flow?
- After $2.0M of capital expenditures, Ginkgo Bioworks's free cash flow was -$168.2M over the trailing twelve months, up 51.3% year over year.
- Where does Ginkgo Bioworks's cash flow data come from?
- Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
